SEC Form 4 · accession 0001209191-15-023545

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Mar 4, 2015

Accepted (ET)

Mar 6, 2015 · 4:29 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Mar 4, 2015	M	1,300	$17.16	A	373,411	D
Common Stock	Mar 4, 2015	M	10,400	$35.64	A	383,811	D
Common Stock^F2,F3	Mar 4, 2015	S	3,780	$120.24	D	380,031	D
Common Stock^F3,F4	Mar 4, 2015	S	6,508	$121.53	D	373,523	D
Common Stock^F3,F5	Mar 4, 2015	S	1,412	$122.21	D	372,111	D
Common Stock	holding	—	—		—	13,286	I	401(k)
Common Stock^F6	holding	—	—		—	136,873	I	Common Stock held in trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F7	$17.16	Mar 4, 2015	M	1,300	D	—	Jul 19, 2015	Common Stock	1,300	25,200	D
Stock Option (right to buy)^F7	$35.64	Mar 4, 2015	M	10,400	D	—	Feb 1, 2016	Common Stock	10,400	489,600	D

F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2Open market sales reported on this line occurred at a weighted average price of $120.24 (range $119.92 to $120.88).
F3Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4Open market sales reported on this line occurred at a weighted average price of $121.53 (range $120.96 to $121.95).
F5Open market sales reported on this line occurred at a weighted average price of $122.21 (range $121.96 to $122.50).
F6Common stock held in grantor retained annuity trusts.
F7Fully vested.